AU2018265241B2 - GARP-TGF-β antibodies - Google Patents

GARP-TGF-β antibodies Download PDF

Info

Publication number
AU2018265241B2
AU2018265241B2 AU2018265241A AU2018265241A AU2018265241B2 AU 2018265241 B2 AU2018265241 B2 AU 2018265241B2 AU 2018265241 A AU2018265241 A AU 2018265241A AU 2018265241 A AU2018265241 A AU 2018265241A AU 2018265241 B2 AU2018265241 B2 AU 2018265241B2
Authority
AU
Australia
Prior art keywords
ser
antibody
leu
tgf
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018265241A
Other languages
English (en)
Other versions
AU2018265241A1 (en
Inventor
Filip BORGIONS
Pierre Coulie
Gitte DE BOECK
Torsten Dreier
Stéphanie LIENART
Sophie Lucas
Lore Mariën
Sebastian VAN DER WONING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Catholique de Louvain
ArgenX BVBA
Original Assignee
Université Catholique de Louvain
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Catholique de Louvain, ArgenX BVBA filed Critical Université Catholique de Louvain
Publication of AU2018265241A1 publication Critical patent/AU2018265241A1/en
Priority to AU2021240255A priority Critical patent/AU2021240255A1/en
Application granted granted Critical
Publication of AU2018265241B2 publication Critical patent/AU2018265241B2/en
Assigned to Université Catholique de Louvain, argenx BV reassignment Université Catholique de Louvain Request to Amend Deed and Register Assignors: ARGENX BVBA, Université Catholique de Louvain
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2018265241A 2017-05-11 2018-05-11 GARP-TGF-β antibodies Active AU2018265241B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021240255A AU2021240255A1 (en) 2017-05-11 2021-09-30 GARP-TGF-ß antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1707561.5A GB201707561D0 (en) 2017-05-11 2017-05-11 GARP-TGF-beta antibodies
GB1707561.5 2017-05-11
PCT/EP2018/062251 WO2018206790A1 (en) 2017-05-11 2018-05-11 GARP-TGF-β ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021240255A Division AU2021240255A1 (en) 2017-05-11 2021-09-30 GARP-TGF-ß antibodies

Publications (2)

Publication Number Publication Date
AU2018265241A1 AU2018265241A1 (en) 2019-11-21
AU2018265241B2 true AU2018265241B2 (en) 2021-11-04

Family

ID=59201573

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018265241A Active AU2018265241B2 (en) 2017-05-11 2018-05-11 GARP-TGF-β antibodies
AU2021240255A Abandoned AU2021240255A1 (en) 2017-05-11 2021-09-30 GARP-TGF-ß antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021240255A Abandoned AU2021240255A1 (en) 2017-05-11 2021-09-30 GARP-TGF-ß antibodies

Country Status (35)

Country Link
US (4) US10479829B2 (enExample)
EP (3) EP4086286A1 (enExample)
JP (2) JP7118135B2 (enExample)
KR (2) KR102664663B1 (enExample)
CN (1) CN110945027B (enExample)
AU (2) AU2018265241B2 (enExample)
BR (1) BR112019023735A8 (enExample)
CA (1) CA3061841C (enExample)
CL (1) CL2019003211A1 (enExample)
CO (1) CO2019013669A2 (enExample)
CR (1) CR20190561A (enExample)
CY (1) CY1125674T1 (enExample)
DK (1) DK3606961T3 (enExample)
DO (1) DOP2019000285A (enExample)
EC (1) ECSP19087742A (enExample)
ES (1) ES2921015T3 (enExample)
GB (1) GB201707561D0 (enExample)
HR (1) HRP20220787T1 (enExample)
HU (1) HUE059237T2 (enExample)
IL (2) IL270236B2 (enExample)
LT (1) LT3606961T (enExample)
MX (1) MX385670B (enExample)
MY (1) MY199335A (enExample)
NZ (1) NZ758647A (enExample)
PE (1) PE20200618A1 (enExample)
PH (1) PH12019502526A1 (enExample)
PL (1) PL3606961T3 (enExample)
PT (1) PT3606961T (enExample)
RS (1) RS63361B1 (enExample)
RU (1) RU2767784C2 (enExample)
SG (1) SG10201914130VA (enExample)
SI (1) SI3606961T1 (enExample)
SM (1) SMT202200284T1 (enExample)
UA (1) UA125534C2 (enExample)
WO (1) WO2018206790A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
CN120022360A (zh) 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
CN114630679A (zh) 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
CA3167427A1 (en) * 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
JP7842690B2 (ja) 2020-02-19 2026-04-08 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
US20230192867A1 (en) * 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
CN117295767A (zh) * 2020-11-11 2023-12-26 Versapeutics公司 针对wnt受体ryk的抗体变体
CN116723861A (zh) * 2020-12-02 2023-09-08 上海复宏汉霖生物技术股份有限公司 抗GARP/TGFβ抗体及使用方法
KR20230169936A (ko) * 2021-01-18 2023-12-18 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 Garp 단백질 항체 및 이의 적용
US20250282857A1 (en) * 2021-03-26 2025-09-11 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20240425571A1 (en) * 2021-10-11 2024-12-26 Ohio State Innovation Foundation Glycoprotein a repetitions predominant (garp)-binding antibodies and uses thereof
PY2336430A (es) 2022-05-18 2023-11-27 Vestaron Corp Variantes de péptidos pesticidas actx
US20260029402A1 (en) 2022-07-22 2026-01-29 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
US20240042020A1 (en) 2022-07-29 2024-02-08 Abbvie Biotherapeutics Inc. Anti-garp-tgf-beta1/pd-1 combination therapy
CN120418286A (zh) 2023-01-09 2025-08-01 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
WO2024164807A1 (zh) * 2023-02-06 2024-08-15 贝达药业股份有限公司 多特异性抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
CA2999819A1 (en) * 2015-09-24 2017-03-30 Daiichi Sankyo Company, Limited Anti-garp antibody

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
WO2007113301A1 (en) 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
KR101492052B1 (ko) 2012-06-26 2015-02-10 (주)대창솔루션 액화가스 운반용 탱크
AU2013310924B2 (en) 2012-08-31 2017-08-03 Argenx Bvba Method for producing antibody molecules having inter-species, intra-target cross-reactivity
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EP2832747A1 (en) 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
EP3484499A4 (en) 2016-07-14 2020-05-13 Scholar Rock, Inc. TGFB ANTIBODIES, METHODS AND USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
CA2999819A1 (en) * 2015-09-24 2017-03-30 Daiichi Sankyo Company, Limited Anti-garp antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. CUENDE ET AL, "Monoclonal antibodies against GARP/TGF-b1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo", SCIENCE TRANSLATIONAL MEDICINE, US, (2015-04-22), vol. 7, no. 284, pages 284ra56 - 284ra56 *

Also Published As

Publication number Publication date
LT3606961T (lt) 2022-07-11
SI3606961T1 (sl) 2022-10-28
CN110945027A (zh) 2020-03-31
IL270236A (enExample) 2019-12-31
US20210324061A1 (en) 2021-10-21
EP4282430A2 (en) 2023-11-29
AU2018265241A1 (en) 2019-11-21
HRP20220787T1 (hr) 2022-09-16
WO2018206790A1 (en) 2018-11-15
UA125534C2 (uk) 2022-04-13
KR102664663B1 (ko) 2024-05-23
CY1125674T1 (el) 2025-05-09
GB201707561D0 (en) 2017-06-28
EP4086286A1 (en) 2022-11-09
DOP2019000285A (es) 2020-07-15
CO2019013669A2 (es) 2020-04-01
CN110945027B (zh) 2023-08-01
PH12019502526A1 (en) 2020-07-20
PT3606961T (pt) 2022-07-04
BR112019023735A8 (pt) 2023-01-31
US20180327487A1 (en) 2018-11-15
US10479829B2 (en) 2019-11-19
AU2021240255A1 (en) 2021-10-28
ES2921015T3 (es) 2022-08-16
RU2019140602A (ru) 2021-06-11
CA3061841A1 (en) 2018-11-15
US10793627B2 (en) 2020-10-06
PL3606961T3 (pl) 2022-08-16
IL305613A (en) 2023-11-01
NZ758647A (en) 2022-07-29
JP7118135B2 (ja) 2022-08-15
CL2019003211A1 (es) 2020-04-24
US20200095311A1 (en) 2020-03-26
KR20240065192A (ko) 2024-05-14
RU2767784C2 (ru) 2022-03-21
SG10201914130VA (en) 2020-03-30
EP3606961A1 (en) 2020-02-12
ECSP19087742A (es) 2020-05-29
KR20200027469A (ko) 2020-03-12
SMT202200284T1 (it) 2022-09-14
CR20190561A (es) 2020-04-04
EP4282430A3 (en) 2024-04-03
MX2019013490A (es) 2021-08-26
JP2020519308A (ja) 2020-07-02
IL270236B1 (en) 2023-10-01
DK3606961T3 (da) 2022-07-04
JP2022169549A (ja) 2022-11-09
US20190375832A1 (en) 2019-12-12
BR112019023735A2 (pt) 2020-06-09
HUE059237T2 (hu) 2022-11-28
MX385670B (es) 2025-03-18
US10875914B2 (en) 2020-12-29
EP3606961B1 (en) 2022-06-01
PE20200618A1 (es) 2020-03-11
CA3061841C (en) 2022-08-09
RU2019140602A3 (enExample) 2021-07-23
MY199335A (en) 2023-10-24
RS63361B1 (sr) 2022-07-29
EP3606961B8 (en) 2022-07-13
IL270236B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US10793627B2 (en) GARP-TGF-β 1 IGG antibodies
US11230603B2 (en) Anti-GARP protein
HK40021303B (en) Garp-tgf-beta antibodies
WO2024183635A1 (en) Muc1 and cd16a antibodies and methods of use
WO2024183637A1 (en) Muc1 antibodies and methods of use
WO2022242682A1 (en) Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ARGENX BV

Free format text: FORMER NAME(S): ARGENX BVBA; UNIVERSITE CATHOLIQUE DE LOUVAIN

Owner name: UNIVERSITE CATHOLIQUE DE LOUVAIN

Free format text: FORMER NAME(S): ARGENX BVBA; UNIVERSITE CATHOLIQUE DE LOUVAIN